IMODIUM COMPLETE CHEWABLE TABLETS TABLET (CHEWABLE)

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

Disponible des:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

Codi ATC:

A07DA53

Designació comuna internacional (DCI):

LOPERAMIDE, COMBINATIONS

Dosis:

2MG; 125MG

formulario farmacéutico:

TABLET (CHEWABLE)

Composición:

LOPERAMIDE HYDROCHLORIDE 2MG; SIMETHICONE 125MG

Vía de administración:

ORAL

Unidades en paquete:

5/10/20

tipo de receta:

OTC

Área terapéutica:

ANTIDIARRHEA AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0231812001; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2014-05-21

Fitxa tècnica

_ _
_ IMODIUM_
_®_
_ Complete _
_Page 1 of 22_
PRODUCT MONOGRAPH
IMODIUM
®
Complete
Loperamide Hydrochloride, 2 mg/ Simethicone, 125 mg
Oral antidiarrheal/antiflatulent agent
McNeil Consumer Healthcare,
Division of Johnson & Johnson Inc.
88 McNabb St.
Markham, Ontario
L3R 5L2
Date of Revision:
May 22, 2019
Submission Control No: 225986
_ _
_ IMODIUM_
_®_
_ Complete _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
8
DOSAGE AND ADMINISTRATION
...............................................................................
8
OVERDOSAGE
..................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 10
STORAGE AND STABILITY
.........................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 11
PART II: SCIENTIFIC INFORMATION
..............................................................................
12
PHARMACEUTICAL INFORMATION
.........................................................................
12
CLINICAL TRIALS
...........................................................................................